Diagnostics and Prognostication of Myelodysplastic Syndromes, Ann Lab Med. nov, vol.37, issue.6, pp.465-74, 2017. ,
WHO classification of tumours of haematopoietic and lymphoid tissues ,
International Agency for Research on Cancer; 2017. 585 p. (World Health Organization classification of tumours) ,
Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts, Leuk Res. janv, vol.37, issue.1, pp.64-70, 2013. ,
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study ,
Molecular Pathogenesis of MDS, Hematol Am Soc Hematol Educ Program, pp.156-60, 2005. ,
The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). ASH Educ Program Book, 12 mai, vol.2015, issue.1, p.307, 2015. ,
Myelodysplastic syndromes: updates and nuances, Med Clin North Am. mars, vol.101, issue.2, p.50, 2017. ,
The genetic basis of myelodysplastic syndromes, Hematol Oncol Clin North Am. avr, vol.24, issue.2, pp.295-315, 2010. ,
The genetic basis of myelodysplasia and its clinical relevance, Blood. 12 déc, vol.122, issue.25, pp.4021-4055, 2013. ,
Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management, Am J Hematol. 1 janv, vol.93, issue.1, pp.129-176, 2018. ,
Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment, Leuk Res. 1 déc, vol.22, issue.12, pp.1123-1159, 1998. ,
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood. 2 juill, vol.126, issue.1, pp.9-16, 2015. ,
The inflammatory microenvironment in MDS, Cell Mol Life Sci. 1 mai, vol.72, issue.10, pp.1959-66, 2015. ,
Autoimmune manifestations associated with myelodysplastic syndromes, Ann Hematol. nov, vol.97, issue.11, pp.2015-2038, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01960324
Société Française d'Hématologie, 2018. ,
Standardizing dysgranulopoiesis in MDS and AML: refining diagnostics and laying the foundation for novel morphological-genetic correlations, Leuk Res. avr, vol.38, issue.4, pp.428-437, 2014. ,
Current pathology practices in and barriers to MDS diagnosis ,
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes, Haematologica. 1 avr, vol.98, issue.4, pp.568-75, 2013. ,
Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors, Haematologica. mai, vol.97, issue.5, pp.723-753, 2012. ,
Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes, Leuk Res. juin, vol.36, issue.6, pp.727-761, 2012. ,
, Haematologica Atlas of Hematologic Cytology
Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas ,
URL : https://hal.archives-ouvertes.fr/hal-01880991
,
Traite Technique D'Hermatologie. Morphologie -Histogenese -Histophysiologie -Histopathologie 2 Volumes von, Jolly J ,
Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes, Leuk Res. avr, vol.38, issue.4, pp.447-53, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01147036
Chromatin Clumping in Mature Leukocytes: A Hitherto Unrecognized Abnormality, Blood, vol.35, issue.5, pp.637-658, 1970. ,
Frequency of Drumsticks in Normal Women and in Patients with Chromosomal Abnormalities, Nature, vol.201, issue.4916, pp.317-319, 1964. ,
Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia, Leukemia Research, vol.45, pp.75-81, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01301508
Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH), Annales de biologie clinique, vol.74, issue.5, pp.525-534, 2016. ,
Incidence of 17p deletions andTP53mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion, Genes, Chromosomes and Cancer, vol.51, issue.12, pp.1086-1092, 2012. ,
The significance of isolated Y chromosome loss in bone marrow metaphase cells from males over age 50 years, Leukemia Research, vol.35, issue.10, pp.1297-1300, 2011. ,
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance, Blood, vol.126, issue.21, pp.2355-2361, 2015. ,
The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes, Leukemia & Lymphoma, vol.56, issue.12, pp.3437-3439, 2015. ,
O-001 Clinical and biological implications of gene mutations in MDS, Leukemia Research, vol.37, issue.22, p.S9, 2013. ,
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.30, issue.27, pp.3376-3382, 2012. ,
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes, Leukemia, vol.30, issue.11, pp.2214-2220, 2016. ,
Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure, Leukemia & Lymphoma, vol.58, issue.11, pp.2532-2539, 2017. ,
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions, Oncotarget, vol.8, issue.43, pp.73483-73500, 2017. ,
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies, Blood, vol.117, issue.17, pp.4552-4560, 2011. ,
Techniques for detecting chromosomal aberrations in myelodysplastic syndromes, Oncotarget, vol.8, issue.37, pp.62716-62729, 2017. ,
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML, Blood, vol.111, issue.3, pp.1534-1542, 2008. ,
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine, Blood Cancer Journal, vol.3, issue.11, pp.e155-e155, 2013. ,
The Use of Flow Cytometry in Myelodysplastic Syndromes: A Review, Frontiers in Oncology, vol.7, 2017. ,
Immunophenotypic clustering of myelodysplastic syndromes, Blood, vol.100, issue.7, pp.2349-2356, 2002. ,
Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes, Blood, vol.108, issue.3, pp.1037-1044, 2006. ,
Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes, Leukemia Research, vol.32, issue.5, pp.699-707, 2008. ,
Flow cytometry « Ogata score » for the diagnosis of myelodysplastic syndromes in a real-life setting. A Latin American experience ,
The 2016 revision to the World Health Organization classification of myelodysplastic syndromes, Journal of Translational Internal Medicine, vol.5, issue.3, pp.139-143, 2017. ,
Syndrome 5q- : caractéristiques hématologiques, physiopathologie et traitement. Hématologie. 29 sept, vol.14, pp.259-69, 2008. ,
, Insuffisances médullaires et autres cytopénies chroniques, Oncologie, vol.10, issue.11, pp.686-689, 2008.
Prognostic scoring systems in MDS, Leukemia Research, vol.36, issue.12, pp.1463-1469, 2012. ,
Revised International Prognostic Scoring System for Myelodysplastic Syndromes, Blood, vol.120, issue.12, pp.2454-2465, 2012. ,
Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine, Annals of Hematology, vol.92, issue.3, pp.411-412, 2012. ,
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q), Blood Cancer Journal, vol.4, issue.8, pp.e242-e242, 2014. ,
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R, Blood. 10 avr, vol.123, issue.15, pp.2333-2375, 2014. ,
Myelodysplastic syndromes current treatment algorithm 2018, Blood Cancer Journal, vol.8, issue.5, 2018. ,
Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome, PLOS ONE, vol.12, issue.3, p.e0172147, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02377929
Deferasirox treatment for myelodysplastic syndromes: ?real-life? efficacy and safety in a single-institution patient population, Annals of Hematology, vol.91, issue.9, pp.1345-1349, 2012. ,
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients, Leukemia Research, vol.34, issue.11, pp.1430-1436, 2010. ,
,
Thrombopoiesis-stimulating agents and myelodysplastic syndromes, British Journal of Haematology, vol.169, issue.3, pp.309-323, 2015. ,
Current therapy of myelodysplastic syndromes, Blood Reviews, vol.27, issue.5, pp.243-259, 2013. ,
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial, Haematologica. juill, vol.98, issue.7, p.1067, 2013. ,
Management of myelodysplastic syndromes after failure of response to hypomethylating agents, Therapeutic Advances in Hematology, vol.10, p.204062071984705, 2019. ,
Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center Experience, Blood, vol.124, issue.21, pp.3264-3264, 2014. ,
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From, 2004. ,
New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types, Leukemia Research, vol.57, pp.78-84, 2017. ,
Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis, American Journal of Clinical Pathology, vol.148, issue.1, pp.49-57, 2017. ,
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome, Leukemia Research, vol.32, issue.1, pp.33-37, 2008. ,
Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes, Leukemia Research, vol.34, issue.8, pp.974-980, 2010. ,
Table 1?source data 1. Human HTML Annokey search results that include hyperlinks to NCBI Gene, GeneRIF and Pubmed databases. ,
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia, Blood, vol.99, issue.9, pp.3129-3135, 2002. ,
Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?, Leukemia Research, vol.27, issue.3, pp.235-242, 2003. ,
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes, New England Journal of Medicine, vol.371, issue.26, pp.2488-2498, 2014. ,
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, vol.126, issue.1, pp.9-16, 2015. ,
What biologic factors predict for transformation to AML?, Best Practice & Research Clinical Haematology, vol.31, issue.4, pp.341-345, 2018. ,
ISCN 2016, 2016. ,
Organisation du suivi des dissections aortiques aiguës. Registre IRAD et registre national SFC-SFR-SCTCV, Les Syndromes aortiques aigus, pp.163-167, 2009. ,
Karyotypic and fluorescent in situ hybridization study of the centromere of chromosome 7 in secondary myeloid neoplasms, Revista Brasileira de Hematologia e Hemoterapia, vol.33, issue.6, pp.425-431, 2011. ,
,
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge, Journal of Clinical Oncology, vol.30, issue.8, pp.820-829, 2012. ,
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes, Haematologica, vol.98, issue.4, pp.568-575, 2012. ,
Recommandations du GFHC pour le compte rendu de résultat de l?hémogramme, Option/Bio, vol.27, issue.553-554, pp.17-21, 2016. ,
Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts, Annals of Hematology, vol.94, issue.4, pp.565-573, 2014. ,
The bone marrow aspirate of healthy subjects, British Journal of Haematology, vol.94, issue.1, pp.206-209, 1996. ,
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms, Blood, vol.121, issue.2, pp.260-269, 2013. ,
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification, Leukemia, vol.21, issue.4, pp.678-686, 2007. ,
Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes, International Journal of Hematology, vol.103, issue.2, pp.227-233, 2015. ,
Myelodysplastic Syndromes, Flow Cytometry in Neoplastic Hematology, vol.58, pp.331-340, 2017. ,
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes, Leukemia. janv, vol.29, issue.1, pp.66-75, 2015. ,
Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome, Leukemia & Lymphoma, vol.58, issue.3, pp.569-577, 2016. ,
The current approach to the diagnosis of myelodysplastic syndromes?, Seminars in Hematology, vol.56, issue.1, pp.15-21, 2019. ,
Clinical significance of Y chromosome loss in hematologic disease, Genes, Chromosomes and Cancer, vol.27, issue.1, pp.11-16, 2000. ,
Isolated Trisomy 15, American Journal of Clinical Pathology, vol.129, issue.3, pp.478-485, 2008. ,
Trisomy 15 Associated with Loss of the Y Chromosome in Bone Marrow, Cancer Genetics and Cytogenetics, vol.105, issue.1, pp.20-23, 1998. ,
,
5. DIE LETZTE ADRESSE, Anruf, Adresse, Appell ,
URL : https://hal.archives-ouvertes.fr/hal-02824353
, ????????????? Mail :??????????????????????????????????? IDENTIFICATION DU PATIENT NOM : 3 premières lettres du nom
L?autobiographie (selon la date de naissance des auteurs), L'autobiographie irlandaise, pp.273-289 ,
Confrontations clinico-biologiques dans la schizophrénie et les troubles bipolaires, PSN, vol.3, issue.2, pp.109-110, 2005. ,
, IV. KRONISCHE MYELOIDE LEUKÄMIE, Acta Medica Scandinavica, vol.105, issue.S112, pp.74-105, 2009.